| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 9.7 | 9.5 |
| Gross profit | 7.3 | 6.7 |
| Profit before tax | -2.1 | -3.6 |
| Net income | -2.1 | -3.2 |
| EPS (diluted, $ a share) | $-0.65 | $-1.01 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +2.6% |
|---|---|
| Gross margin | 75.3% |
| Operating margin | -12.0% |
10-Q filed with the SEC, NASDAQ: CTSO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Cytosorbents Corp: key numbers
- Share price
- $4.16Close, Nov 20
- Market cap
- $16.2M
- Shares outstanding
- 3.15MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Cytosorbents Corp
All →Cytosorbents Capital Raise of $4M
CytoSorbents announced a $4.0 million registered direct offering of common stock and pre-funded warrants, with approximately 75% of the offering subscribed for by existing shareholders and management. The proceeds will be used to repay $3.0 million of outstanding principal under the company's loan agreement with Avenue Capital Group as part of a broader debt restructuring.
- Value
- $4M
- Counterparty
- H.C. Wainwright & Co., LLC
Cytosorbents Financial Results
Cytosorbents Corp reported Q3 2026 financial results, achieving its goal of operating cash flow breakeven (excluding restructuring payments). Revenue grew 3% to $9.7 million, driven by an 18% increase in distributor and strategic partner sales, while the net loss narrowed to $2.1 million.
- Term
- Q3 2026
“The third quarter marked an important financial milestone for CytoSorbents as we achieved our goal of operating cash flow breakeven, excluding restructuring-related payments. This achievement reflects a year of disciplined execution and meaningful improvements in our underlying business.”
Dr. Phillip Chan, Chief Executive Officer
Cytosorbents Financial Results
CytoSorbents reported Q3 2026 financial results, highlighting the achievement of operating cash flow breakeven (excluding restructuring payments). Revenue grew 3% to $9.7 million, while operating loss improved by 59% to $1.2 million due to disciplined cost management and improved gross margins.
- Term
- Q3 2026
“The third quarter marked an important financial milestone for CytoSorbents as we achieved our goal of operating cash flow breakeven, excluding restructuring-related payments. This achievement reflects a year of disciplined execution and meaningful improvements in our underlying business.”
Dr. Phillip Chan, Chief Executive Officer
Cytosorbents Nasdaq/NYSE Compliance Notice
CytoSorbents has regained compliance with Nasdaq's $1.00 minimum bid price requirement after its stock closed at or above that level for 10 consecutive trading sessions. However, the company remains non-compliant with the $35 million Minimum Market Value of Listed Securities (MVLS) requirement and has until December 28, 2026, to resolve this deficiency.
- Counterparty
- Nasdaq
- Term
- until Dec 28, 2026
Cytosorbents CEO Phillip P. Chan Buys $22.6K of Stock
Phillip P. Chan, CEO, bought 3,774 shares of Cytosorbents Corp at $6.00 a share, worth $22.6K in total on Sep 15, 2026. Shares held after the trade: 100,996 (+3.9%).
- Value
- $22.6K
- Shares
- 3,774
- Price
- $6.00
- Role
- CEO
- Holding change
- +3.9%
- Trade date
- Sep 15, 2026
Cytosorbents President and COO Vincent Capponi Buys $10.9K of Stock
Vincent Capponi, President and COO, bought 1,800 shares of Cytosorbents Corp at $6.07 a share, worth $10.9K in total on Sep 14, 2026. Shares held after the trade: 40,114 (+4.7%).
- Value
- $10.9K
- Shares
- 1,800
- Price
- $6.07
- Role
- President and COO
- Holding change
- +4.7%
- Trade date
- Sep 14, 2026